Publication: Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
SAGE Publications
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Collier, T. Lee, Kevin P. Maresca, Marc D. Normandin, Paul Richardson, Timothy J. McCarthy, Steven H. Liang, Rikki N. Waterhouse, and Neil Vasdev. 2017. “Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET.” Molecular Imaging 16 (1): 1536012117736669. doi:10.1177/1536012117736669. http://dx.doi.org/10.1177/1536012117736669.
Research Data
Abstract
The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique 11C and 18F-labeling strategies to synthesize isotopologs of lorlatinib (PF-06463922) which is undergoing phase III clinical trial investigations for treatment of non-small-cell lung cancers with specific molecular alterations. A major goal in cancer therapeutics is to measure the concentrations of this drug in the brain metastases of patients with lung cancer, and penetration of the blood–brain barrier is important for optimal therapeutic outcomes. Our recent publication in Nature Communications employed radiolabeled lorlatinib and positron emission tomography (PET) studies in preclinical models including nonhuman primates (NHPs) that demonstrated high brain permeability of this compound. Our future work with radiolabeled lorlatinib will include advanced PET evaluations in rodent tumor models and normal NHPs with the goal of clinical translation.
Description
Other Available Sources
Keywords
lorlatinib, positron emission tomography, carbon-11, fluorine-18, ALK, ROS1
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service